Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androxal in overweight men with secondary hypogonadism
NCT01532414Phase 3Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Aug 2012
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enclomiphene in secondary hypogonadism (HH) (3 arms), sponsored by Repros Therapeutics Inc. Primary endpoints: Proportion of Androxal Treated Subjects With Testosterone in the Normal Range at 3 months and Subjects With 50% or Greater Decrease in Sperm Concentration at 3 months. Started Aug 2012; status: completed.
02
Drugs
enclomiphene
03
Conditions
secondary hypogonadism (HH)
Beyond the preview
Go deeper on NCT01532414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01532414.